Mumbai, May 23, 2019: West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, is pleased to announce that the NovaGuard® SA Pro safety system – a single-use accessory for prefilled ISO standard 1mL long staked-needle syringes – has won the India Packaging Awards for Excellence in Enhanced User Experience and Excellence in Packaging Design – Shapes and Structures. In addition, the company announced a new product line extension to its AccelTRA® component program, and showcased thought leadership with presentations at the UBM InnoPack Pharma Conference in Mumbai.
The prestigious India Packaging Awards, presented on May 21, 2019 during a ceremony held at the Sahara Star Hotel, are an initiative by UBM to honor the best innovations in the Pharma Packaging space.
“West is honored to receive this prestigious recognition for our NovaGuard SA Pro needle safety system, which is designed to help prevent accidental needlestick injuries,” said Eric Resnick, Vice President & Chief Technology Officer, Innovation & Technology at West. “We appreciate that needlestick injuries are a serious concern for healthcare practitioners, so we developed the NovaGuard system to provide care providers with greater control and protection from potentially life-threatening exposure to harmful diseases when administering injections.”
The NovaGuard SA Pro 1mL device has FDA 510k clearance in the U.S. and meets the European 2010/32/EU directive for the prevention of sharps injuries. Additionally, it can be deployed using a single-handed technique and was designed to prevent pre-activation during the handling of prefilled syringes (PFS). The system is compatible with ISO standard 1mL long glass staked-needle syringes and is transparent for ease of drug extraction, inspection and delivery. The design also facilitates easy assembly of glass prefilled syringes with minimal change parts and changeover time to existing assembly equipment for manufacturers. Additional features of the safety device system include:
West also announced during the InnoPack conference that ready-to-sterilize and ready-to-use gamma sterilized AccelTRA Elastomer Components will soon be available for customers requiring high-performing elastomer components for premium domestic needs or for export to the EU. An extension of the high-performing 4031/45 formula, the components will be available in 13mm and 20mm serum and lyo stopper configurations. The 20mm serum configuration is currently available for sampling and commercial orders; remaining configurations will be available in the coming months.
Additionally, West showcased the following thought leadership at the conference:
Presenters: Milagro Lopez – Director, Segment Marketing, Generics, West
Kok Li Kwang – Manager, Technical Support, Asia Pacific, West
For more information about the NovaGuard SA Pro system, please visit www.westpharma.com/products/prefillable-systems/safety-systems/novaguard-sa-pro.
For more information about West, please visit our website: www.westpharma.com.
Forward-Looking Statements
Certain forward-looking statements are included in this release. They use such words as “new,” “will,” “soon,” “available,” “high-performing,” and other similar terminology. These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that West’s NovaGuard® SA Pro needle safety system or West’s AccelTRA® elastomer components will achieve any level of commercial success. These forward-looking statements involve a number of risks and uncertainties. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: customer decisions to move forward with our new products; customers’ changing inventory requirements and manufacturing plans; and interruptions or weaknesses in our supply chain. This list of important factors is not all inclusive. For a description of certain additional factors that could cause West’s future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled “Risk Factors,” in West’s Annual Report on Form 10-K for the year ended December 31, 2018. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Newsvoir
By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…
By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital …
Kurnool, November 20, 2024: Adoni, Andhra Pradesh, – The Khazi India Foundation is pleased to…
New Delhi, November 20, 2024: Aakash Healthcare marked this year’s Children’s Day with a joyful…
Dr Agarwals Eye Hospital, Bengaluru, is providing free consultations for diabetic patients aged 50 and…
By Ms. Archana S, Senior Nutritionist, Aster Whitefield Hospital, Bengaluru As an essential nutrient, protein…